Skip to main content
Logo
European Innovation Council
private sector

MedTrace Pharma A/S

MedTrace Pharma is working to eliminate diagnostic uncertainty by innovating medical imaging to help HCPs diagnose patients better and faster.

MedTrace Pharma A/S Logo

Overview

Description

Coronary artery disease (CAD) is a disease blocking blood flow to the heart. Identifying patients with limited blood flow is key in improving patient outcomes. 15O-water is the undisputed gold standard tracer for blood flow assessment, with more than 450 publications on the topic. However, the ultra-short half-life of 15O -water, the difficult image analysis and the lack of regulatory approved equipment have limited its use in clinical practice. This limits the transition from current practice (SPECT, with poor accuracy and low throughput) to PET.

With MedTrace’s solution of hardware and analytical software, clinicians all over the world will get routine access to 15O-water PET, achieving unrivalled accuracy at a low-cost while increasing patients’ comfort. MedTrace’s addressable market potential draws on the installed base of current PET scanners (>500,000 worldwide in 2017), tapping into a multi-billion-euro opportunity for every 1% that starts using 15O-water.

Website
Invested amount

EUR 4 261 074.18

Founded

2015

Project
Country
Denmark
Theme
Health